REMEGEN (RemeGen Co., Ltd.) reported a strong turnaround for the three months ended 31 March 2026, moving from a loss a year earlier to solid profitability, driven by higher product sales, reduced research expenses and sizeable fair-value gains on financial assets.

• Revenue rose 24.76% year on year to RMB 656.21 million, reflecting continued growth of commercialised products.

• Net profit attributable to shareholders reached RMB 328.01 million (RMB 0.58 per share) versus a net loss of RMB 254.14 million in the prior-year period. Excluding non-recurring items—chiefly a RMB 364.04 million gain from changes in fair value of financial assets—the company recorded a core loss of RMB 34.99 million.

• Total R&D expenditure fell 36.19% to RMB 209.86 million, cutting the R&D-to-revenue ratio to 31.98% from 62.53% a year earlier. Management attributed the decline to product technology out-licensing.

• Operating cash flow turned positive at RMB 11.32 million, compared with an outflow of RMB 188.32 million in Q1 2025, supported by stronger cash collections from sales.

Balance sheet highlights (31 March 2026):

• Total assets: RMB 7.37 billion, up 1.62% from year-end 2025. • Cash and bank balances: RMB 1.12 billion. • Owners’ equity: RMB 3.93 billion, up 8.86%. • Total liabilities declined to RMB 3.44 billion from RMB 3.64 billion.

Key profitability metrics:

• Weighted average return on equity improved to 8.68% from –13.61%. • Basic and diluted EPS both came in at RMB 0.58, reversing a RMB 0.46 loss per share a year earlier.

The unaudited figures were prepared under PRC accounting standards and reviewed by the board’s audit committee. They have not been audited by independent external auditors. Investors are advised to exercise caution when interpreting the results.